

## Oculus Schedules Fiscal Third Quarter 2008 Financial Results Release and Conference Call

PETALUMA, Calif .-- (BUSINESS WIRE)--

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) today announced that financial results for the 2008 fiscal third quarter ended December 31, 2007, will be released before the U.S. market open on February 7, 2008.

The earnings release will be followed by a conference call at 1:15 p.m. PST (4:15 p.m. EST) on February 7, 2008, to discuss 2008 fiscal third quarter corporate highlights and financial results.

A live broadcast over the Internet will be available at <a href="http://ir.oculusis.com/events.cfm">http://ir.oculusis.com/events.cfm</a> and will be archived for one year. Please log on approximately 30 minutes prior to the presentation in order to register and download the appropriate software.

To listen over the phone, please call 1-877-407-4018 (domestic/toll-free) or 1-201-689-8471 (international). A telephone replay will be available for 30 days after the call at 1-877-660-6853 (domestic/toll-free), or 1-201-612-7415 (international). Please enter account number 3055 and conference identification number 270645.

## **About Oculus**

Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a biocompatible solution containing active oxychlorine compounds. The solutions derived from the Microcyn Technology platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. The technology has also demonstrated wound healing in chronic and acute wounds in clinical investigational studies. It has been commercialized outside of the United States for the treatment of infected wounds.

Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe, Latin America and Japan through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V., Oculus Technologies of Mexico, S.A. de C.V. and Oculus Japan K.K. Oculus' website is <a href="https://www.oculusis.com">www.oculusis.com</a>.

Microcyn is a registered trademark of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

Source: Oculus Innovative Sciences, Inc.